Scolaris Content Display Scolaris Content Display

Vesicular monoamine transporter inhibitors versus placebo for antipsychotic‐induced tardive dyskinesia

Deutetrabenazine (3R,11bR)‐3‐(2‐methylpropyl)‐9,10‐bis(trideuteriomethoxy)‐1,3,4,6,7,11b‐hexahydrobenzo[a]quinolizin‐2‐one
Figuras y tablas -
Figure 1

Deutetrabenazine (3R,11bR)‐3‐(2‐methylpropyl)‐9,10‐bis(trideuteriomethoxy)‐1,3,4,6,7,11b‐hexahydrobenzo[a]quinolizin‐2‐one

Valbenazine (2R,3R,11bR)‐3‐isobutyl‐9,10‐dimethoxy‐1,3,4,6,7,11b‐hexahydro‐2H‐pyrido[2,1‐a]isoquinolin‐2‐yl L‐valinate)
Figuras y tablas -
Figure 2

Valbenazine (2R,3R,11bR)‐3‐isobutyl‐9,10‐dimethoxy‐1,3,4,6,7,11b‐hexahydro‐2H‐pyrido[2,1‐a]isoquinolin‐2‐yl L‐valinate)

Message from one of the participants in the public and patient involvement consultation of service‐user perspectives on tardive dyskinesia research
Figuras y tablas -
Figure 3

Message from one of the participants in the public and patient involvement consultation of service‐user perspectives on tardive dyskinesia research

Table 1. Other Cochrane Reviews in this series

Interventions

Current reference(s) (updates underway)

Anticholinergic medication

Soares 2000; Soares‐Weiser 1997

Benzodiazepines

Bhoopathi 2006

Calcium‐channel blockers

Essali 2011

Cholinergic medication

Tammenmaa 2002

Gamma‐aminobutyric acid agonists

Alabed 2011

Miscellaneous treatments

Soares‐Weiser 2003

Antipsychotic reduction orcessation, or both, and neuroleptics

Soares‐Weiser 2006

Non‐neuroleptic catecholaminergic drugs

El‐Sayeh 2006

Vitamin E

Soares‐Weiser 2011

Figuras y tablas -
Table 1. Other Cochrane Reviews in this series